An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma

Purpose: Metformin combined with the mTOR inhibitor rapamycin showed potential synergistic anti-tumor activity in preclinical studies in pancreatic ductal adenocarcinoma (PDA). This phase 1b study (NCT02048384) was conducted to evaluate the feasibility and activity of metformin +/– rapamycin in the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Bever, Katherine M., Borazanci, Erkut H., Thompson, Elizabeth A., Durham, Jennifer N., Pinero, Kimberly, Jameson, Gayle S., Vrana, Amber, Liu, Meizheng, Wilt, Cara, Wu, Annie A., Fu, Wei, Wang, Hao, Yin, Yafu, Leal, Jeffrey P., Jesus-Acosta, Ana De, Zheng, Lei, Laheru, Daniel A., Von Hoff, Daniel D., Jaffee, Elizabeth M., Powell, Jonathan D., Le, Dung T.
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2020
Matèries:
Priority Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7260120/
https://ncbi.nlm.nih.gov/pubmed/32523648
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27586
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars